Acadian Asset Management
CYCN icon

Acadian Asset Management’s Cyclerion Therapeutics CYCN Stock Holding History

Acadian Asset Management’s Portfolio CYCN Stock Details CYCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-2,236
Closed -$7K – 1697
2023
Q3 		$7K Sell
2,236
-3,201
-59% -$11.5K ﹤0.01% 1605
2023
Q2 		$22K Sell
5,437
-6,161
-53% -$31.9K ﹤0.01% 1639
2023
Q1 		$99K Hold
11,598
– – ﹤0.01% 1397
2022
Q4 		$151K Hold
11,598
– – ﹤0.01% 1350
2022
Q3 		$198K Hold
11,598
– – ﹤0.01% 1215
2022
Q2 		$127K Hold
11,598
– – ﹤0.01% 1304
2022
Q1 		$256K Sell
11,598
-892
-7% -$21.5K ﹤0.01% 1154
2021
Q4 		$428K Buy
+12,490
New +$590K ﹤0.01% 1050
2021
Q1 		– Sell
-2,573
Closed -$157K – 2108
2020
Q4 		$157K Buy
2,573
+606
+31% +$41.3K ﹤0.01% 1630
2020
Q3 		$239K Sell
1,967
-5,688
-74% -$650K ﹤0.01% 1385
2020
Q2 		$905K Buy
7,655
+2,266
+42% +$189K ﹤0.01% 995
2020
Q1 		$285K Buy
5,389
+346
+7% +$24.7K ﹤0.01% 1110
2019
Q4 		$274K Buy
+5,043
New +$471K ﹤0.01% 1217

Other funds holding CYCN

SPC
Slate Path Capital New York $7.22B AUM 110.75% 1-Year Est. Return
MP
MFN Partners Boston, Massachusetts $4.83B AUM 65.74% 1-Year Est. Return
TCP
Tyndall Capital Partners New York $452K AUM 26.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Acadian Asset Management's CYCN Position: Q4 2023 in Review

Acadian Asset Management sold out of Cyclerion Therapeutics (CYCN) in Q4 2023, closing a stake of 2,236 shares — an estimated $7K sold.

Acadian Asset Management first reported a position in CYCN in Q4 2019 and held it in 13 quarters. The position peaked at $905K in Q2 2020. 15 funds tracked by Wall St. Rank hold CYCN as of Q4 2023.

  • Acadian Asset Management reported no remaining Cyclerion Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Acadian Asset Management sold 2,236 Cyclerion Therapeutics shares in Q4 2023, an estimated $7K.
  • Acadian Asset Management first reported a position in Cyclerion Therapeutics in Q4 2019 and held it in 13 quarters.
  • Acadian Asset Management's Cyclerion Therapeutics position peaked at $905K in Q2 2020.
  • 15 funds tracked by Wall St. Rank held Cyclerion Therapeutics as of Q4 2023.

Based on Acadian Asset Management's 13F filing for Q4 2023, filed 13 Feb 2024.